Vestal Point Capital, LP Celldex Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 1,750,000 shares of CLDX stock, worth $41.7 Million. This represents 1.87% of its overall portfolio holdings.
Number of Shares
1,750,000
Previous 198,646
780.96%
Holding current value
$41.7 Million
Previous $3.61 Billion
887.75%
% of portfolio
1.87%
Previous 0.26%
Shares
3 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
68.2MCall Options Held
208KPut Options Held
238K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$145 Million14.83% of portfolio
-
Wellington Management Group LLP Boston, MA5.23MShares$125 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$112 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$94.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$90.9 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.11B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...